8-K: Simulations Plus Reports Strong First Quarter Fiscal 2025 Results Driven by Software Growth

Simulations Plus reported a 31% year-over-year increase in total revenue for the first quarter of fiscal year 2025, primarily driven by strong software growth.

Summary

• Simulations Plus announced its financial results for the first quarter of fiscal year 2025, which ended on November 30, 2024.
• Total revenue reached $18.9 million, a 31% increase compared to the same quarter last year.
• Software revenue grew by 41% to $10.7 million, making up 57% of total revenue.
• Services revenue increased by 19% to $8.2 million, accounting for 43% of total revenue.
• Gross profit was $10.2 million, with a gross margin of 54%.
• Net income was $0.2 million, resulting in a diluted EPS of $0.01, compared to $1.9 million and $0.10 respectively in the prior year.
• Adjusted EBITDA was $4.5 million, representing 24% of total revenue, compared to $3.4 million and 23% in the prior year.
• Adjusted net income was $3.4 million, with an adjusted diluted EPS of $0.17, compared to $3.7 million and $0.18 respectively in the prior year.
• The company reaffirmed its fiscal year 2025 guidance, projecting revenue between $90 million and $93 million, with a software mix of 55% to 60%, an adjusted EBITDA margin of 31% to 33%, and adjusted diluted EPS between $1.07 and $1.20.

Sentiment

Score: 6

Explanation: The document presents mixed results. While revenue growth is strong, the decrease in net income and EPS, along with project delays, temper the overall positive outlook. The reaffirmed guidance provides some reassurance, but the negative financial metrics prevent a higher sentiment score.

Positives

• Strong software revenue growth of 41% indicates high demand for the company's products.
• The 43% growth in MonolixSuite demonstrates the success of this leading-edge solution.
• The 40% growth in the QSP business unit highlights the increasing adoption of their models.
• The company's overall revenue growth of 31% shows a strong start to fiscal year 2025.
• The company is on track to meet its stated guidance for fiscal year 2025.
• The integration of the Adaptive Learning and Insights (ALI) and Medical Communications (MC) business units is progressing well.
• Bookings were especially strong in the Clinical Pharmacology & Pharmacometrics (CPP) and Medical Communications (MC) business units.

Negatives

• Net income decreased significantly to $0.2 million from $1.9 million in the same quarter last year.
• Diluted EPS decreased to $0.01 from $0.10 in the same quarter last year.
• Services revenue growth of 19% was impacted by client-driven data delays.
• The company faced some temporary headwinds in the services segment due to project postponements.
• Adjusted net income decreased to $3.4 million from $3.7 million in the same quarter last year.
• Adjusted diluted EPS decreased to $0.17 from $0.18 in the same quarter last year.

Risks

• The company's ability to integrate the ALI and MC business units could impact future performance.
• The company's ability to meet its stated guidance is subject to various market and economic factors.
• The company's ability to maintain its competitive advantages is crucial for continued success.
• Acceptance of new software and improved versions by customers is essential for revenue growth.
• The general economics of the pharmaceutical industry can affect the company's performance.
• The company's ability to finance growth and attract and retain qualified staff are ongoing risks.
• Market conditions and macroeconomic factors can impact the company's results.
• The company faces ongoing funding challenges and cost constraints in the pharma and biotech sectors.

Future Outlook

The company expects momentum to be strongest in the back half of fiscal year 2025 and is on track to meet its stated guidance. Fiscal year 2025 revenue is projected to be between $90 million and $93 million, with a software mix of 55% to 60%, an adjusted EBITDA margin of 31% to 33%, and adjusted diluted EPS between $1.07 and $1.20.

Management Comments

• Shawn OConnor, Chief Executive Officer, stated that the company is off to a strong start to fiscal 2025 with total revenue increasing by 31% in the first quarter.
• Shawn OConnor noted that the team delivered 41% growth across software platforms, with MonolixSuite being a meaningful contributor with a 43% growth rate.
• Management highlighted a recent commitment from a major pharmaceutical client to fully implement PKanalix, a component of MonolixSuite.
• Management mentioned that the QSP business unit saw 40% growth with strong demand for model licenses.
• Management acknowledged that the services segment faced some temporary headwinds due to client-driven data delays.
• Management stated that bookings were especially strong in the CPP and MC business units.
• Management noted that the integration of the ALI and MC business units is progressing well.

Industry Context

The results reflect the ongoing demand for biosimulation and cheminformatics solutions in the biopharma industry. The strong software growth aligns with the industry's increasing reliance on technology to accelerate drug discovery and development. The temporary headwinds in services revenue may indicate broader challenges in project timelines and data availability within the sector.

Comparison to Industry Standards

• Simulations Plus's 41% software revenue growth is strong compared to industry averages, which typically range from 10-20% for established software companies in the life sciences sector. Companies like Certara and Dassault Systèmes BIOVIA, which also offer simulation software, have reported varying growth rates, but Simulations Plus's growth in this quarter is notable.
• The 19% growth in services revenue is solid, but the temporary headwinds suggest that the company is not immune to project delays, which are common in the consulting and services sector of the pharmaceutical industry. Companies like Syneos Health and IQVIA, which provide clinical research services, also experience fluctuations in project timelines.
• The adjusted EBITDA margin of 24% is within the range of profitability for software and services companies in the life sciences sector. However, companies with higher software margins, such as Veeva Systems, often achieve higher EBITDA margins.
• The company's focus on specific software solutions like MonolixSuite and GastroPlus, and the growth in QSP, positions them well in niche areas of the market. This is similar to how companies like Schrödinger focus on specific computational chemistry solutions.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and EPS, but reassured by the strong revenue growth and reaffirmed guidance.
• Employees may be encouraged by the company's growth and strategic initiatives.
• Customers may benefit from the company's continued investment in software and services.
• Suppliers and creditors may view the company's financial stability positively due to the revenue growth.

Next Steps

• The company will continue to focus on integrating the ALI and MC business units.
• The company will focus on supporting accelerated growth in its distributor network.
• The company will continue to develop its organization to drive growth.
• The company will release GastroPlusX, Monolix R24, and ADMET Predictor Version 12.
• The company will continue its collaboration with USC to develop new AI drug discovery offerings.

Key Dates

Keywords

Simulations Plus, cheminformatics, biosimulation, software, revenue, EBITDA, pharmaceutical, MonolixSuite, QSP, financial results